Erste Asset Management Gmb H Fibrogen Inc Transaction History

Erste Asset Management Gmb H

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 26, 2024	SELL	$7.94 - $12.96 $265,196 - $432,864	-33,400 Closed	0 $0
Q2 2021 Nov 22, 2024	SELL	$18.57 - $35.68 $1.73 Million - $3.33 Million	-93,300 Closed	0 $0
Q3 2020 Nov 22, 2024	BUY	$40.47 - $45.5 $3.78 Million - $4.25 Million	93,300 New	93,300 $3.88 Billion
Q1 2020 Nov 22, 2024	SELL	$23.3 - $45.96 $242,320 - $477,984	-10,400 Reduced 10.55%	88,200 $3.09 Billion
Q4 2019 Nov 22, 2024	BUY	$34.58 - $48.06 $3.41 Million - $4.74 Million	98,600 New	98,600 $4.43 Billion
Q1 2019 Nov 22, 2024	BUY	$42.83 - $59.91 $3.16 Million - $4.42 Million	73,700 New	73,700 $4 Billion
Q4 2018 Nov 26, 2024	BUY	$37.97 - $60.16 $1.27 Million - $2.01 Million	33,400 New	33,400 $1.46 Billion

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $30.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.